Solid Biosciences Inc. filings document regulatory disclosures for a Nasdaq-listed precision genetic medicine company developing gene therapies for rare neuromuscular and cardiac diseases. Its SEC records include Form 8-K reports on operating and financial results, Regulation FD presentations, clinical updates for SGT-003 and the INSPIRE DUCHENNE trial, material agreements, and capital-structure matters.
Proxy filings describe annual stockholder meeting proposals, board classification matters, advisory votes, executive compensation, and equity awards. The filing record also identifies the company’s common stock as listed on The Nasdaq Global Select Market under the SLDB symbol.
Solid Biosciences Inc. reported positive new interim results from its Phase 1/2 INSPIRE DUCHENNE trial of gene therapy SGT-003 in pediatric Duchenne muscular dystrophy. As of the February 23, 2026 cutoff, 40 participants had been dosed at 1E14 vg/kg, with SGT-003 generally well tolerated under a steroid-only prophylactic regimen.
Muscle biopsies in 20 participants at Day 90 and 3 at Day 360 showed robust microdystrophin expression, with mean western blot levels of 60% and 91% of normal and strong beta-sarcoglycan and nNOS localization. Serum biomarkers of muscle damage such as CK, ALT, AST and LDH showed 30–46% mean reductions at Day 90 and sustained improvements at Day 360, consistent with better muscle integrity.
The company also highlighted stabilization-to-improvement in cardiac systolic function by left ventricular ejection fraction, particularly in participants with low-normal baseline values. Solid Biosciences has reached FDA alignment on the randomized, double‑blind, placebo‑controlled Phase 3 IMPACT DUCHENNE trial and expects first dosing in the first quarter of 2026, with additional regulatory and clinical updates planned for mid‑2026, including discussions on a potential accelerated approval pathway for SGT-003.
Solid Biosciences Inc. received a large investment from funds managed by Perceptive. Perceptive Advisors LLC, Joseph Edelman and affiliated funds now report beneficial ownership of 11,969,079 shares of Common Stock, representing 12.9% of 92,883,496 shares outstanding.
Perceptive Life Sciences Master Fund acquired 8,912,655 pre-funded warrants in a private placement at $5.609 per warrant, for an aggregate purchase price of $49.9 million. These pre-funded warrants cannot be exercised if doing so would push Perceptive’s beneficial ownership above 9.99% of Solid’s outstanding shares, so they are not currently exercisable.
The ownership calculation combines shares outstanding as of October 29, 2025 with additional shares issued in the March 9, 2026 private placement. Adam Stone, the Advisor’s Chief Investment Officer, also holds options on 139,933 shares, with 62,433 currently exercisable or exercisable within 60 days.
Solid Biosciences Inc. reported that entities associated with Perceptive Advisors received a grant of pre-funded warrants to acquire 8,912,655 shares of Common Stock. These pre-funded warrants carry a de minimis exercise price of $0.001 per share and were acquired at $5.609 per warrant.
The warrants are directly held by Perceptive Life Sciences Master Fund Ltd., with Perceptive Advisors LLC serving as its investment manager and Joseph Edelman as managing member of the Advisor. The warrants do not expire and are subject to a 9.99% Beneficial Ownership Limitation on exercise. The reporting persons disclaim beneficial ownership beyond any indirect pecuniary interest.
Solid Biosciences Inc. and Bain Capital Life Sciences entities updated their ownership disclosure following a new private financing. The issuer completed a March 2026 private placement of 14,973,257 common shares at $5.61 per share and pre-funded warrants for 27,807,482 shares at $5.609 per warrant. Bain Capital Life Sciences Opportunities IV, L.P. bought a pre-funded warrant for 5,347,593 shares for $29,994,649.14, using its own working capital.
Across related Bain Capital Life Sciences funds, the group reports collective beneficial ownership of 9,808,819 shares of common stock, or 9.99% of the class, after applying 9.99% beneficial ownership blockers on pre-funded warrant exercises. Individual reporting entities show stakes ranging from 0.1% to 8.8% of the outstanding common stock.
RA Capital Management and affiliated funds report beneficial ownership of 9,663,926 shares of Solid Biosciences common stock, representing 9.9% of the class. The position is held through RA Capital Healthcare Fund, the RA Capital Nexus Fund, a managed account and pre-funded warrants.
In February 2026, the healthcare fund bought 354,936 shares in open-market trades at a weighted average price of $6.49 per share for total consideration of $2,304,350.99. On March 6, 2026, it also acquired 4,456,327 pre-funded warrants in a private placement for $24,995,538, each exercisable at $0.001 per share but capped by a 9.99% beneficial ownership blocker.
The March 2026 private placement issued 14,973,257 new shares and 27,807,482 additional pre-funded warrants to institutional investors. Solid Biosciences agreed in a registration rights agreement to register for resale the new shares and the common stock underlying the March 2026 pre-funded warrants.
Solid Biosciences Inc. entered into a private placement with institutional investors to sell 14,973,257 common shares at $5.61 per share and pre-funded warrants for 27,807,482 shares at $5.609 per warrant, for expected gross proceeds of about $240.0 million and net proceeds of about $226.8 million.
The company expects to report preliminary cash, cash equivalents and available-for-sale securities of roughly $187.9 million as of December 31, 2025, and believes its cash plus net placement proceeds can fund operations into the first half of 2028. Pre-funded warrants are immediately exercisable at $0.001 per share and are subject to beneficial ownership limits of 4.99% or 9.99%, up to a maximum of 19.99%. The company agreed to register the resale of all securities issued and to pay liquidated damages of 1.0% of each investor’s amount per 30-day period if specified registration deadlines are not met.
Solid Biosciences Inc. entered into a private placement with institutional investors to sell 14,973,257 common shares at $5.61 per share and pre-funded warrants for 27,807,482 shares at $5.609 per warrant, for expected gross proceeds of about $240.0 million and net proceeds of about $226.8 million.
The company expects to report preliminary cash, cash equivalents and available-for-sale securities of roughly $187.9 million as of December 31, 2025, and believes its cash plus net placement proceeds can fund operations into the first half of 2028. Pre-funded warrants are immediately exercisable at $0.001 per share and are subject to beneficial ownership limits of 4.99% or 9.99%, up to a maximum of 19.99%. The company agreed to register the resale of all securities issued and to pay liquidated damages of 1.0% of each investor’s amount per 30-day period if specified registration deadlines are not met.
Solid Biosciences Inc. President and CEO Alexander Cumbo reported a combination of RSU vesting and a related tax sale. On February 13, 2026, he acquired 30,031 shares of common stock at $0.00 per share through the conversion of restricted stock units, increasing his directly held common stock.
On February 18, 2026, he sold 16,644 shares of common stock in an open‑market transaction at a weighted average price of $5.8233 per share to cover withholding taxes following the RSU vesting, under a pre‑existing automatic sales instruction that is not a discretionary trade. After these transactions, he directly owned 235,405 shares of common stock and 60,063 RSUs that vest over four years from the February 13, 2024 grant date.
Solid Biosciences filed a Form 144 reporting a proposed sale of Common Stock tied to the settlement of vested restricted stock units on 02/18/2026. The filing lists proposed/settled share movements including examples of prior sales by a selling holder, including Brooks Gabriel: 28,335 shares and 12,616 shares.
The notice ties the 02/18/2026 entry to compensation (RSU settlement); proceeds and specific distribution methods are shown for prior sales in the excerpt.
Cumbo Alexander filed a Form 144 reporting proposed sales of Common Stock. The notice lists three transactions: 12/03/2025 sale of 10,808 shares for $55,228.88, 02/02/2026 sale of 80,258 shares for $516,612.72, and 02/04/2026 sale of 48,913 shares for $315,079.69.
The excerpt also shows the settlement of 16,644 vested restricted stock units on 02/18/2026 reported as issuer compensation.
Solid Biosciences Inc. Chief Regulatory Officer Jessie Hanrahan reported insider equity activity involving restricted stock units and related tax sales. On February 13, 2026, she acquired 8,125 shares of common stock through the exercise of restricted stock units at a price of $0.00 per share. On February 18, 2026, she sold 4,134 shares of common stock at a weighted average price of $5.8233 per share, with actual sale prices ranging from $5.23 to $6.14, to cover withholding taxes following RSU vesting under a pre-established automatic sell-to-cover instruction. After these transactions, she held 74,318 shares of common stock and 16,250 restricted stock units.